Episode Details

This study investigates whether using a sirolimus-coated balloon during angioplasty offers better outcomes for patients with infrainguinal artery disease compared to standard, uncoated balloons. Researchers conducted a large-scale clinical trial to determine if the drug-coated device could more effectively prevent major adverse limb events, such as emergency amputations or the need for repeat procedures. The results revealed that patients treated with the sirolimus-coated balloon experienced significantly fewer complications and required fewer follow-up interventions within one year. Ultimately, the evidence suggests that this medicated approach provides a superior clinical benefit without increasing the risk of death or other serious side effects.